The Food and Drug Administration Friday approved the first liquid biopsy companion diagnostic that uses next-generation sequencing technology to identify patients with specific gene mutations in a deadly form of metastatic non-small cell lung cancer.

“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” said Tim Stenzel, M.D., director of FDA’s Office of In Vitro Diagnostics and Radiological Health.

In other news, the agency Friday approved a new intraveneous opioid for managing acute pain in adults in hospital and other controlled clinical settings, such as inpatient and outpatient procedures. The drug, Olinvyk (oliceridine), has a maximum recommended daily dose limit of 27 milligrams.

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks comments through July 1 to inform development of a potential Consumer Assessment of Healthcare…
Headline
Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results…
Headline
Inpatient rehabilitation facilities and long-term care hospitals have until April 6 to access updated provider preview reports of their quality data. The…
Headline
Robyn Begley, chief nursing officer for the AHA and CEO of the American Organization for Nursing Leadership, today issued a statement in response to a decision…
Chairperson's File
One week in early March every year is designated as Patient Safety Awareness Week, a national recognition to encourage everyone to learn more about health care…
Headline
To support National Patient Safety Awareness Week, which starts Sunday, the American Society for Health Care Risk Management has developed free tip sheets and…